English

Insider transactions

EDGAR

Neurogene Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-15.

Open-market purchases (code P): 0 transactions, — shares
Open-market sales (code S): 17 transactions, 41,580 shares; Sum of shares × price per share: 1,133,591.8388

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–32 of 32

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
Date	Reporting owner	Code	Acquired or disposed	Shares	Price per share, as filed	Value (derived)	Shares owned after	Direct or indirect	Rule 10b5-1 box	Notes	Source
2026-09-22 Filed 2026-10-02	McMinn Rachel Director · Officer: Chief Executive Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock	Acquired (A)	756	25.32	19,141.92 Derived: shares × price per share. Exact value 19141.92.	1,345,063	Direct (D)	No	F1 F1 Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.	Open filing 0001606302-26-000007 Read from the filing’s XML Dispute this row
2026-09-22 Filed 2026-10-02	McMinn Rachel Director · Officer: Chief Executive Officer	M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Derivative security: Stock Option (Right to Buy) — underlying Common Stock (756) — exercise price 25.32	Disposed (D)	756	0	—	0	Direct (D)	No	F2 F2 This option is fully vested and exercisable.	Open filing 0001606302-26-000007 Read from the filing’s XML Dispute this row
2026-07-07 Filed 2026-07-07	Cvijic Christine Mikail Director · Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	4,200	36.134	151,762.8 Derived: shares × price per share. Exact value 151762.800.	84,040	Direct (D)	Yes	F1, F4, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.	Open filing 0001543663-26-000017 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-07	Cvijic Christine Mikail Director · Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	600	36.021	21,612.6 Derived: shares × price per share. Exact value 21612.600.	88,240	Direct (D)	Yes	F1, F2, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.	Open filing 0001543663-26-000017 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-02	Cvijic Christine Mikail Director · Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	2,531	34.579	87,519.449 Derived: shares × price per share. Exact value 87519.449.	90,370	Direct (D)	Yes	F1, F4, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000015 Read from the filing’s XML Dispute this row
2026-07-02 Filed 2026-07-02	Cvijic Christine Mikail Director · Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	1,530	35.227	53,897.31 Derived: shares × price per share. Exact value 53897.310.	88,840	Direct (D)	Yes	F1, F5, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000015 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02	Cvijic Christine Mikail Director · Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	739	34.059	25,169.601 Derived: shares × price per share. Exact value 25169.601.	92,901	Direct (D)	Yes	F1, F2, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000015 Read from the filing’s XML Dispute this row
2026-05-06 Filed 2026-05-08	Cvijic Christine Mikail Director · Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	4,800	30.0732	144,351.36 Derived: shares × price per share. Exact value 144351.3600.	98,440	Direct (D)	Yes	F1, F2, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000013 Read from the filing’s XML Dispute this row
2026-05-06 Filed 2026-05-08	Cvijic Christine Mikail Director · Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	4,800	32.4358	155,691.84 Derived: shares × price per share. Exact value 155691.8400.	93,640	Direct (D)	Yes	F1, F4, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000013 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-07	Shafer Christina Officer: Chief Commercial Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (120,000) — exercise price 28.94	Acquired (A)	120,000	0	—	120,000	Direct (D)	No	F1 F1 This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.	Open filing 0001934412-26-000006 Read from the filing’s XML Dispute this row
2026-03-26 Filed 2026-03-30	Cvijic Christine Mikail Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	2,558	21.6247	55,315.9826 Derived: shares × price per share. Exact value 55315.9826.	103,240	Direct (D)	Yes	F1, F2, F3 F1 On March 26, 2026, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.91, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000011 Read from the filing’s XML Dispute this row
2026-03-26 Filed 2026-03-30	Jordan Julie Officer: Chief Medical Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	828	21.8932	18,127.5696 Derived: shares × price per share. Exact value 18127.5696.	12,472	Direct (D)	Yes	F1, F2, F3 F1 On March 26, 2026, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.68 to $22.19, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Consist of (a) 5,600 restricted stock units, which vest annually in equal installments on March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units which vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.	Open filing 0001968554-26-000005 Read from the filing’s XML Dispute this row
2026-03-26 Filed 2026-03-30	McMinn Rachel Director · Officer: Chief Executive Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	3,352	22.0749	73,995.0648 Derived: shares × price per share. Exact value 73995.0648.	1,344,307	Direct (D)	Yes	F1, F2, F3 F1 On March 26, 2026, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67to $22.50, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.	Open filing 0001606302-26-000005 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-17	Cobb Stuart Officer: Chief Scientific Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	3,991	20.41	81,456.31 Derived: shares × price per share. Exact value 81456.31.	33,303	Direct (D)	Yes	F1, F2, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.	Open filing 0001994301-26-000004 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-17	Cobb Stuart Officer: Chief Scientific Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	2,658	21.34	56,721.72 Derived: shares × price per share. Exact value 56721.72.	30,645	Direct (D)	Yes	F1, F4, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.	Open filing 0001994301-26-000004 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-17	Cobb Stuart Officer: Chief Scientific Officer	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	148	22.08	3,267.84 Derived: shares × price per share. Exact value 3267.84.	30,497	Direct (D)	Yes	F1, F5, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.	Open filing 0001994301-26-000004 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-17	Cvijic Christine Mikail Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	2,387	20.4224	48,748.2688 Derived: shares × price per share. Exact value 48748.2688.	107,456	Direct (D)	Yes	F1, F2, F3 F1 On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000007 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-17	Cvijic Christine Mikail Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	1,395	21.2451	29,636.9145 Derived: shares × price per share. Exact value 29636.9145.	106,061	Direct (D)	Yes	F1, F4, F3 F1 On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000007 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-17	Cvijic Christine Mikail Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	263	22.0195	5,791.1285 Derived: shares × price per share. Exact value 5791.1285.	105,798	Direct (D)	Yes	F1, F5, F3 F1 On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000007 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03	Cvijic Christine Mikail Officer: President and CFO	S Open market or private sale of non-derivative or derivative security Common Stock	Disposed (D)	4,800	25.1096	120,526.08 Derived: shares × price per share. Exact value 120526.0800.	109,843	Direct (D)	Yes	F1, F2, F3 F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000005 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	McMinn Rachel Director · Officer: Chief Executive Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	25,900	0	—	1,347,659	Direct (D)	No	F1, F2 F1 Consist of 25,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 Includes (a) 23,900 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 25,900 restricted stock units granted on February 20, 2029, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Due to an administrative error, the amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024. This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person.	Open filing 0001606302-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	McMinn Rachel Director · Officer: Chief Executive Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Common Stock (155,100) — exercise price 17.64	Acquired (A)	155,100	0	—	155,100	Direct (D)	No	F3 F3 This option represents the right to purchase 155,100 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.	Open filing 0001606302-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Freedland Cory S. Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (12,050) — exercise price 17.64	Acquired (A)	12,050	0	—	12,050	Direct (D)	No	F1 F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.	Open filing 0001832569-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Noonberg Sarah B. Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (12,050) — exercise price 17.64	Acquired (A)	12,050	0	—	12,050	Direct (D)	No	F1 F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.	Open filing 0001706301-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Cobb Stuart Officer: Chief Scientific Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	16,500	0	—	37,294	Direct (D)	No	F1, F2 F1 Consist of 16,500 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 Consist of (a) 13,594 restricted stock units remaining from a grant of 20,391 restricted stock units granted on March 13, 2024, which vests annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 7,200 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.	Open filing 0001994301-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Jordan Julie Officer: Chief Medical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	4,900	0	—	13,300	Direct (D)	No	F1, F2 F1 Consist of 4,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 Consist of (a) 8,400 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.	Open filing 0001968554-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Jordan Julie Officer: Chief Medical Officer	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Common Stock (29,600) — exercise price 17.64	Acquired (A)	29,600	0	—	29,600	Direct (D)	No	F3 F3 This option represents the right to purchase 29,600 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.	Open filing 0001968554-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	PALEKAR ROHAN Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (12,050) — exercise price 17.64	Acquired (A)	12,050	0	—	12,050	Direct (D)	No	F1 F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.	Open filing 0001628280-26-011325 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	BAFFI ROBERT Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (12,050) — exercise price 17.64	Acquired (A)	12,050	0	—	12,050	Direct (D)	No	F1 F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.	Open filing 0001274826-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Cvijic Christine Mikail Officer: President and CFO	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock	Acquired (A)	22,000	0	—	114,643	Direct (D)	No	F1, F2 F1 Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic.	Open filing 0001543663-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Cvijic Christine Mikail Officer: President and CFO	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (Right to Buy) — underlying Common Stock (131,900) — exercise price 17.64	Acquired (A)	131,900	0	—	131,900	Direct (D)	No	F3 F3 This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.	Open filing 0001543663-26-000002 Read from the filing’s XML Dispute this row
2026-02-20 Filed 2026-02-24	Woods Keith Director	A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (12,050) — exercise price 17.64	Acquired (A)	12,050	0	—	12,050	Direct (D)	No	F1 F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.	Open filing 0001996804-26-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–50 of 84

Institutional holders, largest position first, as filed
Manager	Shares or principal	Value as filed	Change from the prior quarter	Source
BlackRock, Inc. Partly reported under another manager	1,471,936 SH	40,949,259 dollars	Higher by 413,953 Prior quarter: 1,057,983	Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC	711,290 SH	19,788,088 dollars	Higher by 174,765 Prior quarter: 536,525	Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager	630,859 SH	17,399,092 dollars	Higher by 426,579 Prior quarter: 204,280	Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager	549,269 SH	15,280,664 dollars	Higher by 324,947 Prior quarter: 224,322	Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager	417,651 SH	11,619,051 dollars	Higher by 246,362 Prior quarter: 171,289	Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager	412,768 SH	11,486,618 dollars	Higher by 119,586 Prior quarter: 293,182	Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
FMR LLC Partly reported under another manager	383,249 SH	10,661,987 dollars	Higher by 87,688 Prior quarter: 295,561	Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Tyro Capital Management LLC	304,401 SH	8,468,436 dollars	Not in the prior quarter’s filings read	Open filing 0001915395-26-000018 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager	221,090 SH	6,150,724 dollars	Higher by 29,366 Prior quarter: 191,724	Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Jones Hill Capital LP	217,700 SH	6,056,414 dollars	Not in the prior quarter’s filings read	Open filing 0002102314-26-000006 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC	174,262 SH	4,847,969 dollars	Higher by 78,661 Prior quarter: 95,601	Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager	168,509 SH	4,687,920 dollars	Not in the prior quarter’s filings read	Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager	107,949 SH	3,003,141 dollars	Higher by 1,289 Prior quarter: 106,660	Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
VANGUARD FIDUCIARY TRUST CO	104,643 SH	2,911,168 dollars	Higher by 30,381 Prior quarter: 74,262	Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager	87,700 SH	2,440,802 dollars	Higher by 55,072 Prior quarter: 32,628	Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
BLAIR WILLIAM CO/IL	79,081 SH	2,200,033 dollars	Lower by 67,824 Prior quarter: 146,905	Open filing 0001104659-26-124894 Filed 2026-11-10 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager	61,953 SH	1,758,845 dollars	Higher by 71 Prior quarter: 61,882	Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager	38,710 SH	1,076,912 dollars	Higher by 9,969 Prior quarter: 28,741	Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Nuveen, LLC Partly reported under another manager	35,994 SH	1,001,353 dollars	Higher by 8,170 Prior quarter: 27,824	Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Raiffeisen Bank International AG	34,000 SH	965,260 dollars	Unchanged Prior quarter: 34,000	Open filing 0002044885-26-000005 Filed 2026-10-28 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager	30,063 SH	836,353 dollars	Higher by 6,733 Prior quarter: 23,330	Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
Quadrature Capital Ltd Partly reported under another manager	27,147 SH	755,230 dollars	Higher by 2,827 Prior quarter: 24,320	Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row
ALPS ADVISORS INC	26,528 SH	738,009 dollars	Higher by 10,488 Prior quarter: 16,040	Open filing 0001398344-26-019318 Filed 2026-11-03 Dispute this row
TD ASSET MANAGEMENT INC	20,028 SH	568,595 dollars	Not in the prior quarter’s filings read	Open filing 0001193125-26-460060 Filed 2026-11-13 Dispute this row
RHUMBLINE ADVISERS	18,074 SH	502,811 dollars	Higher by 3,921 Prior quarter: 14,153	Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
JANE STREET GROUP, LLC Option: Put Partly reported under another manager	17,000 SH	472,940 dollars	Not in the prior quarter’s filings read	Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager	16,758 SH	466,209 dollars	Not in the prior quarter’s filings read	Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
Quantinno Capital Management LP	15,196 SH	422,753 dollars	Not in the prior quarter’s filings read	Open filing 0001759654-26-000011 Filed 2026-11-13 Dispute this row
Creative Planning Partly reported under another manager	14,933 SH	415,436 dollars	Higher by 4,352 Prior quarter: 10,581	Open filing 0001540235-26-000006 Filed 2026-11-02 Dispute this row
Magnetar Financial LLC	13,816 SH	384,361 dollars	Not in the prior quarter’s filings read	Open filing 0001104659-26-126450 Filed 2026-11-13 Dispute this row
Empowered Funds, LLC Partly reported under another manager	12,551 SH	349,169 dollars	Not in the prior quarter’s filings read	Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
Rafferty Asset Management, LLC	11,591 SH	322,462 dollars	Not in the prior quarter’s filings read	Open filing 0001999371-26-025241 Filed 2026-11-13 Dispute this row
Universal- Beteiligungs- und Servicegesellschaft mbH Partly reported under another manager	11,047 SH	307,328 dollars	Not in the prior quarter’s filings read	Open filing 0002057170-26-000022 Filed 2026-11-10 Dispute this row
Virtus Investment Advisers, LLC Partly reported under another manager	10,905 SH	303,377 dollars	Lower by 339 Prior quarter: 11,244	Open filing 0000019481-26-000011 Filed 2026-11-12 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager	10,205 SH	283,903 dollars	Lower by 10,200 Prior quarter: 20,405	Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
Vanguard Global Advisers, LLC	9,642 SH	268,240 dollars	Higher by 4,788 Prior quarter: 4,854	Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
CITIGROUP INC Partly reported under another manager	9,629 SH	267,878 dollars	Higher by 1,761 Prior quarter: 7,868	Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
BARCLAYS PLC Partly reported under another manager	9,427 SH	262,259 dollars	Higher by 6,117 Prior quarter: 3,310	Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
JANE STREET GROUP, LLC Option: Call Partly reported under another manager	8,800 SH	244,816 dollars	Not in the prior quarter’s filings read	Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
KEYBANK NATIONAL ASSOCIATION/OH Partly reported under another manager	7,947 SH	221,086 dollars	Not in the prior quarter’s filings read	Open filing 0001089877-26-000030 Filed 2026-11-04 Dispute this row
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM Partly reported under another manager	7,491 SH	208,400 dollars	Unchanged Prior quarter: 7,491	Open filing 0000938076-26-000015 Filed 2026-11-13 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager	6,358 SH	176,879 dollars	Higher by 368 Prior quarter: 5,990	Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
Mitsubishi UFJ Asset Management Co., Ltd. Partly reported under another manager	6,040 SH	168,033 dollars	Lower by 50 Prior quarter: 6,090	Open filing 0001193125-26-447983 Filed 2026-11-05 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager	4,431 SH	123,270 dollars	Higher by 2,533 Prior quarter: 1,898	Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Police Firemen's Retirement System of New Jersey Partly reported under another manager	4,093 SH	113,867 dollars	Higher by 247 Prior quarter: 3,846	Open filing 0002040686-26-000007 Filed 2026-11-09 Dispute this row
China Universal Asset Management Co., Ltd.	3,651 SH	103,652 dollars	Higher by 1,136 Prior quarter: 2,515	Open filing 0001906594-26-000005 Filed 2026-10-28 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager	3,172 SH	88 dollars	Not in the prior quarter’s filings read	Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
SIMPLEX TRADING, LLC Option: Put	3,100 SH	86,242 dollars	Higher by 3,000 Prior quarter: 100	Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager	1,438 SH	40,710 dollars	Not in the prior quarter’s filings read	Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
Ameritas Investment Partners, Inc. Partly reported under another manager	1,401 SH	38,976 dollars	Higher by 392 Prior quarter: 1,009	Open filing 0001055980-26-000008 Filed 2026-11-13 Dispute this row

Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

SAMSARA BIOCAPITAL, LLC 1,717,127 SH
Casdin Capital, LLC 1,545,361 SH
Redmile Group, LLC 1,412,199 SH
RTW INVESTMENTS, LP 1,362,456 SH
EcoR1 Capital, LLC 1,271,342 SH
BAKER BROS. ADVISORS LP 991,691 SH
Balyasny Asset Management L.P. 818,706 SH
Trails Edge Capital Partners, LP 714,885 SH
TORONTO DOMINION BANK 681,337 SH
JENNISON ASSOCIATES LLC 518,582 SH
CITADEL ADVISORS LLC 408,982 SH
GREAT POINT PARTNERS LLC 352,180 SH
ArrowMark Colorado Holdings LLC 342,453 SH
Driehaus Capital Management LLC 143,528 SH
Point72 Asset Management, L.P. 141,920 SH
MOORE CAPITAL MANAGEMENT, LP 141,636 SH
Rock Springs Capital Management LP 106,750 SH
NORTHERN TRUST CORP 103,641 SH
GOLDMAN SACHS GROUP INC 101,276 SH
SUSQUEHANNA INTERNATIONAL GROUP, LLP 92,400 SH
DAFNA Capital Management LLC 89,032 SH
Woodline Partners LP 83,835 SH
Trexquant Investment LP 73,762 SH
XTX Topco Ltd 55,424 SH
SCHRODER INVESTMENT MANAGEMENT GROUP 52,300 SH
MILLENNIUM MANAGEMENT LLC 42,734 SH
Sixth Street Partners Management Company, L.P. 32,742 SH
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 32,742 SH
WELLINGTON MANAGEMENT GROUP LLP 31,393 SH
CITADEL ADVISORS LLC 26,700 SH
JANE STREET GROUP, LLC 26,089 SH
Seven Fleet Capital Management LP 22,060 SH
BRIDGEWAY CAPITAL MANAGEMENT, LLC 18,781 SH
AQR CAPITAL MANAGEMENT LLC 15,061 SH
SUSQUEHANNA INTERNATIONAL GROUP, LLP 14,700 SH
ALLIANCEBERNSTEIN L.P. 13,770 SH
Mariner, LLC 12,260 SH
BANK OF AMERICA CORP /DE/ 11,124 SH
D. E. Shaw Co., Inc. 9,781 SH
WELLS FARGO COMPANY/MN 9,471 SH
Pale Fire Capital SE 9,460 SH
PRICE T ROWE ASSOCIATES INC /MD/ 8,896 SH
Brevan Howard Capital Management LP 8,387 SH
ADAR1 Capital Management, LLC 7,800 SH
Invesco Ltd. 6,658 SH
MetLife Investment Management, LLC 5,932 SH
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 5,207 SH
NEW YORK STATE COMMON RETIREMENT FUND 4,200 SH
ROYAL BANK OF CANADA 2,406 SH
SIMPLEX TRADING, LLC 1,500 SH

Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
A change is the difference between two quarter-end snapshots, not a trade.
A position reported under another manager may also appear in that manager’s filing; rows are not added together.
Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
Holder	Percent of class	Shares held	Event date	Form	Source
PRUDENTIAL FINANCIAL INC Common	11.2	2,231,357.00	09/30/2026 Filed 2026-10-07	SCHEDULE 13G	Open filing 0001137774-26-000205 Dispute this row
Jennison Associates LLC Common Stock	11.1	2,229,082	09/30/2026 Filed 2026-10-06	SCHEDULE 13G	Open filing 0000053417-26-000058 Dispute this row
Trails Edge Capital Partners, LP Common Stock, $0.000001 par value per share	4.5	714,885.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001493152-26-038383 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Stock, $0.000001 par value per share	4.5	714,885.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001493152-26-038383 Dispute this row
Ortav Yehudai Common Stock, $0.000001 par value per share	4.5	714,885.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001493152-26-038383 Dispute this row
Redmile Group, LLC Common Stock, $0.000001 par value	9.9	1,572,202.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 7	Open filing 0001104659-26-097193 Dispute this row
Jeremy C. Green Common Stock, $0.000001 par value	9.9	1,572,202.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 7	Open filing 0001104659-26-097193 Dispute this row
Redmile Biopharma Investments I, L.P. Common Stock, $0.000001 par value	5.1	812,033.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G/AAmendment 7	Open filing 0001104659-26-097193 Dispute this row
BALYASNY ASSET MANAGEMENT L.P. Common Stock	5.18	818,706.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G	Open filing 0001172661-26-003430 Dispute this row
BAM GP LLC Common Stock	5.18	818,706.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G	Open filing 0001172661-26-003430 Dispute this row
Balyasny Asset Management Holdings LP Common Stock	5.18	818,706.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G	Open filing 0001172661-26-003430 Dispute this row
Dames GP LLC Common Stock	5.18	818,706.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G	Open filing 0001172661-26-003430 Dispute this row
Dmitry Balyasny Common Stock	5.18	818,706.00	06/30/2026 Filed 2026-08-14	SCHEDULE 13G	Open filing 0001172661-26-003430 Dispute this row
Redmile Group, LLC Common Stock, $0.000001 par value	9.9	1,557,179.00	12/31/2025 Filed 2026-02-17	SCHEDULE 13G/AAmendment 6	Open filing 0001104659-26-016440 Dispute this row
Jeremy C. Green Common Stock, $0.000001 par value	9.9	1,557,179.00	12/31/2025 Filed 2026-02-17	SCHEDULE 13G/AAmendment 6	Open filing 0001104659-26-016440 Dispute this row
Redmile Biopharma Investments I, L.P. Common Stock, $0.000001 par value	4.8	749,610.00	12/31/2025 Filed 2026-02-17	SCHEDULE 13G/AAmendment 6	Open filing 0001104659-26-016440 Dispute this row
Trails Edge Capital Partners, LP Common Stock	5.1	785,000.00	12/08/2025 Filed 2025-12-15	SCHEDULE 13G	Open filing 0001493152-25-027814 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Stock	5.1	785,000.00	12/08/2025 Filed 2025-12-15	SCHEDULE 13G	Open filing 0001493152-25-027814 Dispute this row
Ortav Yehudai Common Stock	5.1	785,000.00	12/08/2025 Filed 2025-12-15	SCHEDULE 13G	Open filing 0001493152-25-027814 Dispute this row
EcoR1 Capital, LLC Common Stock	9.9	1,442,902.00	09/30/2025 Filed 2025-11-14	SCHEDULE 13G/AAmendment 1	Open filing 0000935836-25-000698 Dispute this row
Oleg Nodelman Common Stock	9.9	1,442,902.00	09/30/2025 Filed 2025-11-14	SCHEDULE 13G/AAmendment 1	Open filing 0000935836-25-000698 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock	8.6	1,249,344.00	09/30/2025 Filed 2025-11-14	SCHEDULE 13G/AAmendment 1	Open filing 0000935836-25-000698 Dispute this row
Commodore Capital LP Common Stock, $0.000001 par value	3.0	427,866.00	06/30/2025 Filed 2025-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001831942-25-000013 Dispute this row
Commodore Capital Master LP Common Stock, $0.000001 par value	3.0	427,866.00	06/30/2025 Filed 2025-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001831942-25-000013 Dispute this row
Baker Bros. Advisors LP Common Stock, par value $0.000001 per share	7.0	991,691.00	06/30/2025 Filed 2025-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001104659-25-078656 Dispute this row
Baker Bros. Advisors (GP) LLC Common Stock, par value $0.000001 per share	7.0	991,691.00	06/30/2025 Filed 2025-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001104659-25-078656 Dispute this row
Julian C. Baker Common Stock, par value $0.000001 per share	7.0	991,804.00	06/30/2025 Filed 2025-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001104659-25-078656 Dispute this row
Felix J. Baker Common Stock, par value $0.000001 per share	7.0	991,804.00	06/30/2025 Filed 2025-08-14	SCHEDULE 13G/AAmendment 1	Open filing 0001104659-25-078656 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,024,280 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing year	Filings read
2015	1
2016	204,322
2017	202,494
2018	202,048
2019	193,638
2020	144,184
2021	224,474
2022	40,015
2023	199,811
2024	117,969
2025	235,520
2026	254,026

Filings made before the SEC required XML are listed, not extracted.

Back to Neurogene Inc.